Andrew D. RuskinPartnerK&L Gates LLPWebsitewww.klgates.comOrganization ProfileFull ProfileConnectEmailTwitterLinkedIn202-778-9415 Professional Biography Andrew Ruskin is a partner in the firm’s Washington, D.C. office. He is a member of the health care and FDA practice group. Areas of Focus Health Care and FDA Food, Drugs, Medical Devices, and Cosmetics (FDA) More Legal and Business Bylines From Andrew D. Ruskin Rural Emergency Hospitals — Transformative Change or Limited Impact? [PODCAST] - (Posted On Wednesday, March 22, 2023) Recent Developments to the 340B Drug Pricing Program [PODCAST] - (Posted On Thursday, December 15, 2022) New Data Available Under the Hospital Price Transparency Rule [PODCAST] - (Posted On Thursday, November 17, 2022) Genesis Healthcare and the 340B Program Patient Definition [PODCAST] - (Posted On Tuesday, August 09, 2022) Supreme Court Issues Decision Favorable to Hospitals on 340 B Payment Reduction: What to Do Next - (Posted On Tuesday, June 21, 2022) Medicare Reimbursement for Community Hospital Residency Programs [PODCAST] - (Posted On Monday, January 31, 2022) 2022 OPPS Final Rule Overview: CMS Finalizes Policies on 340B, Hospital Price Transparency, and Inpatient-Only List - (Posted On Monday, November 08, 2021) An Update on the CMS Hospital Price Transparency Rule [PODCAST] - (Posted On Thursday, October 21, 2021) CMS Proposes to Increase Penalties for Hospital Price Transparency Noncompliance - (Posted On Thursday, July 22, 2021) 340B Update: Supreme Court Accepts Certiorari in 340B Payment Reduction Case - (Posted On Thursday, July 08, 2021) Pagination Page 1 Next page Next › Current Legal Analysis China’s State Council Releases Antitrust Guidelines for the Pharmaceutical Sector Covering Reverse Payments and Evergreening by: Aaron Wininger Corporate Transparency Act Reporting Remains Stayed—For Now by: Kevin E. Gaunt , Carleton Goss California Pay Data Report Filing Platform Opens on February 3, 2025: A Preview of What Is to Come by: Christopher W. Olmsted , James A. Patton FCC Postpones Effective Date of One-to-One Consent Rule by: Richard B. Newman How to Sign 300 Cases Per Month with PPC Advertising: Breaking Down the Costs by: Jason Hennessey OFCCP Ordered to Stop All Enforcement Activity and Close Open Audits Under Revoked Executive Order 11246 by: Laura A. Mitchell , Lisa B. Marsh 5 Trends to Watch in 2025: AI and the Israeli Market by: Joey T. Shabot White House “Regulatory Freeze” Directive Pauses Most Federal Rulemaking by: Allan S Bloom Upcoming Events Jan 30 2025 Employer-Based Immigration Changes Under the Trump Administration: Navigating the Shifting Landscape Jan 28 2025 Antibody Drug Conjugates Keep Growing: What You Need to Know Jan 28 2025 Fashion Law 2024 Year in Review Jan 28 2025 U.S. Data Privacy Litigation Print
